Select Page

New data on Eli Lilly’s weight-loss drug shows its outlook is bright

New data on Eli Lilly’s weight-loss drug shows its outlook is bright

Eli Lilly’s office in La Jolla, California.

Konrad Fiedler | Bloomberg | Getty Images

The launch of Eli Lilly‘s weight-loss drug Zepbound — a key pillar of our investment thesis in the pharmaceuticals giant — is going swimmingly in the U.S., Jefferies said Friday.

About The Author

Leave a reply

Your email address will not be published. Required fields are marked *

RECENT REVIEWS

Recent Videos

Loading...